Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

Completed · Phase 2

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.

Key facts

Study ID: NCT02343952
Run by: Nasser Hanna, M.D.
People needed: 93
Starts: 2015-03-09
Expected to finish: 2021-01-01
Last updated by the study team: 2023-09-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histological or cytological evidence of NSCLC
Must have unresectable or inoperable stage IIIA or IIIB disease. Patients are considered unresectable or inoperable based on the judgment of the treating physician
Must have completed concurrent chemoradiation with a standard chemotherapy regimen (either cisplatin/etoposide or carboplatin/paclitaxel) and a dose of radiation ranging from 59.4-66.6Gy
Must have stable disease or disease response as evidenced on CT evaluation a minimum of 28 days and a maximum of 56 days following the completion of chemoradiation
Women of childbearing potential must be willing to use two methods of contraception or abstain from heterosexual activity from the point of registration through 120 days after the last dose of study drug
Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of the study drug through 120 days after the last dose of the study drug
Age ≥ 18 years at the time of consent
Written informed consent and HIPAA authorization for release of personal health information

You may not qualify if…

Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
Active central nervous system (CNS) metastases. Subjects must undergo a head computed tomography (CT) scan or brain MRI within 28 days prior to registration for protocol therapy to exclude brain metastases if symptomatic or without prior brain imaging
Treatment with any investigational agent within 28 days prior to registration for protocol therapy
Prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer, other than standard concurrent chemoradiation as described above
Prior therapy with a PD-1, PD-L1, or CTLA-4 inhibitor or a lung cancer-specific vaccine therapy
Presence of metastatic disease (stage IV NSCLC) is not allowed. Subjects must be evaluated with a PET scan within 28 days prior to registration for protocol therapy to exclude metastatic disease
No active second cancers
Evidence of active autoimmune disease requiring systemic treatment within the past 90 days or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study
Interstitial lung disease or history of pneumonitis requiring treatment with corticosteroids
Diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within 7 days of first dose of study drug
History of psychiatric illness or social situations that would limit compliance with study requirements
Clinically active infection as judged by the treating investigator (≥ Grade 2 by CTCAE v4) including known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator

Where it is running

City of Hope Comprehensive Cancer Center — Duarte, California, United States
Fort Wayne Oncology & Hematology, Inc. — Fort Wayne, Indiana, United States
IU Health Goshen Hospital — Goshen, Indiana, United States
Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
IU Health Central Indiana Cancer Centers — Indianapolis, Indiana, United States
Community Regional Cancer Care — Indianapolis, Indiana, United States
IU Health Arnett Cancer Center — Lafayette, Indiana, United States
Horizon Oncology Research, Inc. — Lafayette, Indiana, United States
IU Health at Ball Memorial Hospital — Muncie, Indiana, United States
Oncology Hematology Associates of SW Indiana — Newburgh, Indiana, United States
Northern Indiana Cancer Research Consortium — South Bend, Indiana, United States
University of Louisville, James Graham Brown Cancer Center — Louisville, Kentucky, United States
Nebraska Cancer Specialists — Omaha, Nebraska, United States
Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
University of Virginia Health System — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.